• de
  • en
deen

International

Berlin Chemie
  • About us
    • BERLIN-CHEMIE
    • MENARINI Group
    • Our History
    • Our Goal
    • Executive Board
    • Contact
  • Responsibility
    • Code of Conduct
    • Sustainability & social commitment
    • Code of practice for business partners
  • Press
    • News and Press Releases
    • Media library
  • Jobs & Careers
  • About us
    • BERLIN-CHEMIE
      • Manufacturing & Quality assurance
      • Business Development
    • MENARINI Group
    • Our History
    • Our Goal
    • Executive Board
    • Contact
  • Responsibility
    • Code of Conduct
    • Sustainability & social commitment
    • Code of practice for business partners
  • Press
    • News and Press Releases
    • Media library
  • Jobs & Careers
  • Home >>
  • Contact >>
  • Purchasing Terms >>
  • Quality Requirements API / EXC >>
  • Data Protection Information Notice for Healthcare Professionals >>
  • Data Protection Information Notice for Patients >>
  • Privacy >>
  • Disclaimer >>
  • Imprint >>
  • Sitemap >>
  • Change cookie settings »

News and Press Releases

Press|News and Press Releases
  • News and Press Releases
  • Media library

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in

Monday, January 30, 2023
Read more

LAST NEWS

Christiane von der Eltz becomes new member of the Executive Board of BERLIN-CHEMIE responsible for the Pharma Germany Division

5/3/2022
Read more

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

11/4/2021
Read more

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

10/20/2021
Read more

Menarini Pills of Art Junior project launched: Video clips made by the younger generations for children and teenagers

4/9/2021
Read more

CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

11/13/2020
Read more

Menarini Group: committed to fighting today's COVID-19 pandemic with an eye to averting similar health crises in the future

10/27/2020
Read more
Previous1234NextLast

News archive

Archive

  • Expand/Collapse 2023 (2)
    • 2023, January (2)
  • Expand/Collapse 2022 (5)
    • 2022, October (1)
    • 2022, September (1)
    • 2022, July (1)
    • 2022, May (2)
  • Expand/Collapse 2021 (3)
    • 2021, November (1)
    • 2021, October (1)
    • 2021, April (1)
  • Expand/Collapse 2020 (7)
    • 2020, November (1)
    • 2020, October (1)
    • 2020, July (1)
    • 2020, June (2)
    • 2020, May (1)
    • 2020, January (1)
  • Expand/Collapse 2019 (1)
    • 2019, September (1)
  • Expand/Collapse 2018 (5)
    • 2018, December (1)
    • 2018, October (1)
    • 2018, September (1)
    • 2018, March (2)
  • Expand/Collapse 2017 (4)
    • 2017, June (1)
    • 2017, March (2)
    • 2017, January (1)
  • Expand/Collapse 2016 (6)
    • 2016, December (2)
    • 2016, November (1)
    • 2016, October (1)
    • 2016, May (1)
    • 2016, March (1)

 

Responsibility >>

BERLIN-CHEMIE

International >>

SCROLL TO TOP Berlin Chemie
Berlin Chemie
  • Home
  • Contact
  • Privacy
  • Change cookie settings »
  • Purchasing Terms
  • Quality Requirements API / EXC
  • Imprint
  • Fair Play Menarini
  • Data Protection Information Notice for Healthcare Professionals
  • Data Protection Information Notice for Patients
  • Disclaimer
  • Sitemap

CONTACT
BERLIN-CHEMIE AG - Glienicker Weg 125 - 12489 Berlin - Germany
Tel.: +49 30 6707-0
Directons: » Contact us

© 2023 BERLIN-CHEMIE AG